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Abstract 
 Prenatal genetic diagnostic testing methods are commonly used for high-risk pregnancies 
in order to gain information about the embryo or fetus. There are many different technologies 
that can be used for prenatal testing, each which comes with its own advantages and 
disadvantages. One screening method that is becoming increasingly reliable is cell free fetal 
DNA (cffDNA) testing. The cffDNA screen analyzes fetal DNA that is present in the maternal 
bloodstream during a pregnancy. This cffDNA can be separated from other blood components 
and sequenced, which will then provide information about the likelihood of a fetus having a 
chromosomal abnormality or a single gene disorder. There are three main DNA sequencing 
methods: Massively Parallel Shotgun Sequencing (MPSS), Digital Analysis of Specific Regions 
(DANSR), and Single Nucleotide Polymorphism (SNP)-based sequencing. The cffDNA 
screening method has very high accuracy for detecting abnormal numbers of chromosomes 
(aneuploidies), specifically the three copies of chromosome 21 in Down syndrome, for which 
this screening method is the most accurate non-invasive prenatal test. Benefits of cffDNA 
screening include that it is non-invasive and has a zero chance of increasing the risk of 
spontaneous termination of a fetus, a risk that is more of a concern for invasive prenatal 
diagnostic procedures such as chorionic villus sampling and amniocentesis. The accuracy of the 
cffDNA screen will continue to improve as technologies progress; but until that time, it is best 
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Introduction 
 When a female becomes pregnant, she has the option to go through prenatal genetic 
diagnosis testing in order to gain information about the fetus or embryo (1). There are many 
reasons to undergo prenatal genetic diagnosis, many of which are associated with high-risk 
pregnancies where there is a higher than average likelihood of having a baby with a genetic 
defect, such as Down syndrome (Trisomy 21) or Cystic Fibrosis. Some causes of high-risk 
pregnancies include advanced maternal age (usually over 35), having a previous child with a 
chromosome abnormality, or one of the parents being a carrier of a monogenic disorder (2). The 
risk of having a child with an abnormal number of chromosomes, a condition called aneuploidy, 
increases dramatically in females with advanced maternal age (3) (Figure 1).  
 
Figure 1. Probability of chromosomal abnormality in the neonate as a function of maternal age. 
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Prenatal genetic diagnosis modalities include both invasive and non-invasive procedures. 
Invasive procedures include amniocentesis and chorionic villus sampling, where sample 
collection is followed by fluorescent in situ hybridization (FISH) with colored probes or DNA 
amplification and sequencing. Chromosomal abnormalities such as Trisomy 12 (Down 
syndrome) can be detected by FISH analysis (Figure 2.)  
 
Figure 2. Spectral karyotyping using FISH analysis revealing a trisomy 21 aneuploidy. 
 
Non-invasive testing involves ultrasounds and/or blood biochemical assessments such as 
the Quad screen. However, these non-invasive methods report risk and likelihood rather than 
definitive answers, which are current goals of researchers in the field (1). One of the newest and 
most promising tests is Cell Free Fetal DNA (cffDNA). This test uses fetal DNA that is found in 
the mother’s bloodstream (Figure 3) to screen for any disorders, such as chromosome 
aneuploidies or monogenic diseases and can even determine fetal sex and fetal RhD status (3). 
This wide range of applications demonstrates how promising the cffDNA test is for prenatal 
diagnosis and explains the dramatic increase in usage, with a total of 4-6 million pregnant 
women using this screen since its inception as of 2017 (4).  
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Figure 3. Cell free fetal DNA in the maternal bloodstream. 
 
Origin and Discovery of Cell Free Fetal DNA 
 Cell free fetal DNA was first discovered in 1997 (5). Previously, researchers had reported 
that DNA from tumors was present in blood circulation (5). This finding led others to 
hypothesize that fetal DNA may be circulating in the mother’s bloodstream. To test this, 
researchers took the serum and plasma of pregnant women and ran a polymerase chain reaction 
(PCR) to amplify Y chromosome-specific DNA fragments (5). Since females do not have Y 
chromosomes, any Y chromosomal DNA in the serum or plasma would have to have come from 
a male fetus. In their testing, they were successful in being able to find Y chromosome DNA 
fragments in 21 out of 30 maternal serum samples and 24 out of 30 maternal plasma samples 
from females carrying a male fetus (5). They did not find any Y chromosomal DNA in the 
samples from the non-pregnant control women nor in the women carrying female fetuses. This 
study also determined that fetal DNA concentration in maternal circulation increases throughout 
pregnancy, an observation that has been confirmed by other studies that found it increases at a 
rate of 0.1 % weekly between 10 and 20 weeks and then increases by 1% weekly until delivery 
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(5,6). Further studies have determined that the fetal DNA comes from the apoptosis of 
syncytiotrophoblast cells which form the outermost layer of the placenta (6). 
 
cffDNA Screening Procedure 
The procedure for screening the cffDNA begins with a blood draw from the mother. 
Since there are higher levels of maternal DNA in the bloodstream than the fetal DNA, the draw 
needs to take place when the fetal fraction is high enough (6) (Figure 4). The fetal fraction is the 
proportion of total DNA in the bloodstream that is fetal DNA. The fetal fraction is approximately 
11 to 13 percent of the total DNA present in the mother’s bloodstream during the late first 
trimester/early second trimester (6). Fetal fractions less than 4% are too low to be used in this 
screening method which is why this procedure is not performed until after the 10th week of 
gestation (4). 
 
Figure 4. Fraction of total blood DNA originating from the fetal placenta is the fetal fraction. 
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Once the blood is drawn, the plasma is separated from the platelets and red and white 
blood cells through centrifugation, and then DNA purification will be performed on the plasma 
to isolate the fragmented DNA that will be tested (7). Currently, there are many methods that are 
used when analyzing DNA that is purified from the plasma. One of them is real time PCR, but 
this method is expensive and time consuming (3). Other methods that are being used more 
frequently, as studies continuously prove their effectiveness, are random sequencing and targeted 
sequencing (4). Random sequencing is also known as Massively Parallel Shotgun Sequencing 
(MPSS) and involves sequencing millions of overlapping DNA fragments from every 
chromosome (8). Targeted sequencing involves amplifying and sequencing regions of DNA on 
chromosomes of interest. A promising targeted sequencing method involves sequencing DNA 
containing single nucleotide polymorphisms (SNPs) on specific chromosomes of interest (4). 
These methods have been successful and have their own advantages as well as limitations. 
 
Random Sequencing: Massively Parallel Shotgun Sequencing 
(MPSS) 
 In this method, all the DNA fragments that are isolated from the maternal blood will be 
sequenced, including both fetal and maternal DNA. Most studies used Illumina sequencing as the 
sequencing method of choice, and then used Solexa to map the sequences to the genome (7).  
Illumina sequencing is a DNA sequencing method that determines the DNA sequence of 
fragmented DNA through the use of adaptors, bridge amplification, and sequencing using 
fluorescently tagged nucleotides. Once the sequencing is finished, there will be DNA sequences 
for all the DNA fragments in the sample which will then be analyzed using Solexa, which is a 
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computer software that aligns the overlapping DNA sequence reads with their respective 
chromosome. The number of reads per chromosome are then counted and converted to a 
percentage which are then compared with the normal percentages of a euploid genome. If the 
percentages fall in the accepted range, then it can be determined that the fetus is euploid. 
However, if a percentage is abnormal, then an aneuploidy is expected. For instance, the normal 
percentage of chromosome 21 fragments is 1.3 percent of total chromosomal DNA (6). If the 
screen finds that a percentage higher than 1.3 percent is attributed to chromosome 21, then it is 
expected that the fetus will be aneuploid for chromosome 21 which will cause the higher than 
expected percentage (Figure 5). The same principle is used for other common aneuploidies, such 
as trisomy 18, trisomy 13, and sex chromosome aneuploidies. Since this method uses overall 
percentages of all the DNA sequencing reads together, including the mother with a normal 
number of chromosome 21, it is not necessary to differentiate maternal and fetal DNA, which 
makes it easier to use than other uncommon methods (7).  
 
Figure 5.  Results of Massively Parallel Shotgun Sequencing (MPSS) based on the ratio of 
sample sequence tags to normal sequence tags for chromosome 21. 
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Targeted Sequencing: Digital Analysis of Specific Regions (DANSR) 
and Single Nucleotide Polymorphisms (SNPs) 
 In this targeted sequencing method, there are two approaches that are commonly used. 
One is very similar to the MPSS discussed above, except instead of randomly sequencing 
fragments from every chromosome, it specifically targets fragments from the chromosomes of 
interest, such as 21, 18, 13, X, and Y. This method is commonly referred to as DANSR (Digital 
Analysis of Specific Regions) because it targets loci on specific chromosomes (8). Like MPSS, 
DANSR requires a comparison to known proportions of chromosomal DNA in order to provide a 
result.  
The other approach uses single nucleotide polymorphisms (SNPs) on chromosomes of 
interest. SNPs on target chromosomes are amplified with PCR and sequenced (4). Then, the 
ratios between SNPs are determined and compared with the expected ratio. For instance, if the 
ratio for one chromosome was found to be 1:1, then it would be predicted to be normal and 
euploid. If the ratio for a different chromosome was 2:1, which is abnormal, then it would be 
predicted that that chromosome would be aneuploid (4). Since this approach compares the ratios 
of SNPs, it does not require a euploid reference for percentages as the other methods do (8). This 
method is also able to detect triploidy as well, which is something the other methods are unable 
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Accuracy and Effectiveness of cffDNA screening 
 Not only is the procedure for cffDNA screening simple, it also has provided a useful 
method for detecting chromosomal aneuploidies. In 2016, a meta-analysis of cffDNA studies 
was published (9). This meta-analysis had a strict selection process to remove any studies with 
bias and reviewed 41 different studies that used cffDNA to screen for Down syndrome (T21), 
Edwards syndrome (T18), and Patau syndrome (T13). The results reported that cffDNA 
screening had a sensitivity of 99.3% and specificity of 99.9% for Down syndrome. For Edwards 
syndrome the sensitivity was 97.4% and the specificity was 99.9%. For Patau syndrome the 
sensitivity was 97.4% and the specificity was 99.9% (Figure 6). 
T21, T18, and T13 Meta-Analysis Results Sensitivity Specificity 
Down syndrome (T21) 99.3% 99.9% 
Edwards syndrome (T18) 97.4% 99.9% 
Patau syndrome (T13) 97.4% 99.9% 
 
Figure 6.  Results from a meta-analysis (9) performed on cffDNA screening accuracies in 2016 
on trisomy 21, trisomy 18, and trisomy 13. 
 
A separate meta-analysis was done for sex chromosome aneuploidies that gave a 
detection rate of 90.3% and a false positive rate of 0.23% for monosomy X, and a detection rate 
of 93% and false positive rate of 0.14% for the sex chromosome trisomies (47, XXX; 47, XXY; 
and 47, XYY) (Figure 7) (10).  
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Sex Chromosome Meta-Analysis Results Detection Rate False Positive Rate 
Monosomy X 90.3% 0.23% 
Sex Chromosome trisomies (47, XXX; 
47, XXY; and 47, XYY) 
93% 0.14% 
 
Figure 7. Results from a meta-analysis (10) performed on cffDNA screening in 2015 on sex 
chromosome aneuploidies. 
 
Risks and Limitations of cffDNA Screening 
 While cffDNA screening has very high detection rates for chromosome aneuploidies, 
especially trisomy 21, there is not 100% accuracy with the test, but other procedures such as 
amniocentesis and chorionic villus sampling (CVS) have essentially 100% accuracy due to their 
respective methods. Due to the lack of 100% accuracy, the cffDNA test is considered only a 
screen and not a diagnostic test (9). Another problem with this test is that it is reliant on a high 
fetal fraction of DNA. If the fetal fraction is not high enough, then the cffDNA test is 
inconclusive. Causes of low fetal fractions include young gestational age (earlier than 10 weeks), 
maternal obesity, and fetal karyotype (6). That is, Trisomy 21 causes a higher fetal fraction, but 
trisomy 18, monosomy X, and overall triploidy (69, XXY) have lower than normal fetal fractions 
and can cause test failures (6). Triploidy rarely results in a live birth, as the chromosome 
abnormalities are too severe. The fact that one of the causes of test failure is part of what the test 
is screening for, is not ideal.  
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Another downside to the cffDNA screen is that the DNA it screens comes from the 
placenta instead of the fetus. The DNA from the placenta and fetus are usually the same since 
they come from the same fertilized egg, but differences can exist between the two. 
Approximately 0.1% of clinical cases analyzing cffDNA found that the placental DNA did not 
match the fetal karyotype (11). A common cause of this is confined placental mosaicism, which 
is when the placenta has chromosome abnormalities while the fetus does not (11) (Figure 8). 
CVS also samples cells from the placenta and thus has this same issue. 
 
 Figure 8. Illustration of confined placental mosaicism, as well as other mosaicisms. 
 
Despite the negatives, this cffDNA screen has some distinct advantages over other testing 
methods. One of these is that there is zero risk of spontaneous termination of the fetus with 
cffDNA collection. Both amniocentesis and CVS have approximately a 1% risk of spontaneous 
termination (1). This risk is significant enough that it may prevent many pregnant women from 
getting invasive testing done, but since cffDNA does not carry that risk, it is a good option for 
women concerned about the risks of amniocentesis or CVS, especially women with advanced 
maternal age who have spent a long time trying to conceive. Additionally, the procedure for 
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cffDNA screening is less invasive than amniocentesis and CVS, requiring only a blood draw. 
Amniocentesis requires extracting amniotic fluid and CVS requires the removal of chorionic villi 
cells (1,2). These more invasive procedures carry more risks, such as higher risks of infection, 
risk of spontaneous termination discussed above, and risk of misdiagnosis from confined 
placental mosaicism which can lead to more complications (2).  
 Another risk associated with any prenatal testing is the emotional and psychological toll 
that the woman could experience. If the woman is informed that her fetus contains an 
abnormality then she may begin considering terminating the pregnancy, even if this is something 
she had not considered an option before. Not knowing either the presence or absence of an 
abnormality is more comforting to some people, and cffDNA can remove that comfort. However, 
some people desire to know regardless of if termination is an option for them so they can be 
better prepared for the baby if an abnormality is present. Emotional and psychological damage is 
not often assessed when going over the positives and negatives of prenatal testing and should be 
considered more frequently, although the lack of risk of spontaneous termination already 
removes some of the potential damage if cffDNA testing is used. 
  
Conclusions 
 Cell free fetal DNA analysis has proven to be a reliable and effective screening method 
for chromosomal aneuploidies. It is most accurate at detecting trisomy 21, but it also has high 
accuracy for trisomy 18, 13, and sex chromosome aneuploidies (9). It is the best of the non-
invasive tests for trisomy 21 detection, although detection of the other aneuploidies is equal to or 
worse than other testing, such as the combined test, which uses ultrasound as well as a blood 
Chris Henry 14 
 
biochemical assessment (10). However, since testing for trisomy 21 is the most desired, the 
testing for other trisomies is usually just a benefit of prenatal testing for trisomy 21 and not the 
goal, so the superiority of cffDNA screening for trisomy 21 testing is most important (10). The 
application of cffDNA testing for all the known chromosome aneuploidies proves that it is useful 
for prenatal genetic testing, and the lack of significant risks associated with this screen make it 
an option for a greater population compared with the invasive testing procedures. This screening 
method is continuously gaining improvements through new discoveries that make it both less 
expensive and more accurate (3). As this process improves it will overcome some of the 
limitations it currently has, but until that time, this method is best used as a preliminary screen 
for high-risk pregnancies (cost permitting) with positive results being followed up by invasive 
testing if desired by the parent(s) (6). 
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